The labeled rules for a missed Zepbound dose are short, and they assume full doses. A missed dose can be given within four days, or 96 hours. Past that, it is skipped and the regular weekly schedule resumes. Two doses are never given within three days, or 72 hours, of each other. Nothing in that guidance describes a partial injection.
The two numbers, and what they take for granted
Both figures exist to keep exposure from stacking. Tirzepatide is dosed once weekly because of how long it persists in the body, and the 96-hour and 72-hour limits mark the edges where a late dose stops being a late dose and starts being a doubled one. The label also allows the weekly day itself to be moved, provided that 72-hour separation is kept.
What makes the arithmetic work is that each injection is a defined amount. The label’s presentations are built around that: single-dose pens and vials hold one dose, and the multi-dose vial and single-patient-use KwikPen hold four weekly doses of a single strength. Zepbound covers weight reduction with long-term maintenance and moderate to severe obstructive sleep apnea in adults with obesity; Mounjaro is the tirzepatide label for glycemic control in type 2 diabetes. Neither label contains a rule for a fraction of a dose, because neither product is supplied in fractions.
A partial injection is not a bridge
The reasoning behind trying is understandable. Supply runs short, the next refill is days out or unaffordable, and stretching what is on hand feels like the responsible choice compared with stopping. It is not, for three reasons that have nothing to do with rule-following.
The first is that the amount cannot be established. There is no validated home method for measuring a partial dose of a product supplied in fixed presentations, and the label instructs that Zepbound not be transferred from a pen into a syringe. The second is sterility. Single-dose presentations contain no antimicrobial preservative, so a container that is punctured, partly used, and stored is being asked to behave in a way it was never tested for. The third is interpretive. After a gap covered by an unknown amount, nobody can say what the following weeks are showing, and the prescriber’s safest option is often to restart from a known position, which spends more time than the gap did.
What one missed week actually costs
Less than people fear. A single missed injection inside an established weekly pattern is a minor event, and the label’s own instruction to skip and resume reflects that. Anxiety about the gap causes more improvising than the gap itself justifies.
Sustained interruption is a different matter, and the evidence on it is clear. In a randomized trial of continued tirzepatide treatment for maintenance of weight reduction, participants who switched to placebo after an open-label lead-in regained a substantial share of what they had lost, while those who continued kept going. A separate extension of a semaglutide obesity trial found a comparable pattern after withdrawal. Those were different molecules in different trials and are not a head-to-head comparison, but the direction is consistent, and a recent review of weight regain after discontinuation of GLP-1 based therapy frames the issue as physiology and follow-up rather than personal failure.
The distinction that matters practically is between one skipped week and a pattern of rationing. The first is noise. The second is a treatment plan quietly failing.
What to bring to the next contact
| What happened | What the labeling establishes | What to raise |
|---|---|---|
| Dose remembered within four days | It can be given, then the regular schedule resumes | Nothing, unless it is becoming a pattern |
| More than four days have passed | Skip it and take the next dose on the scheduled day | Whether symptoms change when the schedule restarts |
| Wanting to move the weekly day | Permitted, provided 72 hours separate the two doses | Confirm the new day so the record matches reality |
| Two injections landed close together | Doses are not given within 72 hours of each other | Report it, with dates, before the next one is due |
| A refill is late or unaffordable | No labeled workaround exists | Coverage status, channel, and whether a lower labeled dose fits the budget |
| Weeks were covered by an improvised amount | No labeled or studied basis for it | Say so plainly, so the next months can be read |
| Several doses missed in a row | Nothing specific in the missed-dose section | Whether restarting at a lower step is appropriate |
Where the same gap keeps recurring, the fix is a steadier supply route rather than a smaller injection, and the routes worth comparing publish enough to compare. LillyDirect carries the manufacturer’s single-dose vials, Henry Meds runs a monitored monthly program, and HealthRX posts what supervised Zepbound costs, so a patient can judge which cadence and price actually fit before a shipment slips again. A dependable refill schedule closes more gaps than any home workaround.
Recurring gaps are an access problem, not a memory problem
Population data support that reading. A United Kingdom cohort study of real-world persistence and dose titration with GLP-1 receptor agonists found that many patients neither reach nor hold the doses the trials used, and interruption is common rather than exceptional. When gaps repeat, the cause is usually cost, coverage, or supply, and the fix belongs in those systems.
The available routes are concrete. Lilly sells single-dose vials through its own self-pay channel below list. Commercially insured patients may qualify for the manufacturer savings program. A denial can go through internal appeal and then an independent external review. Medicare Part D coverage turns on the indication a drug is prescribed for rather than on the drug alone, which is worth checking rather than assuming. Anyone comparing a supervised cash-pay route should ask a compounded GLP-1 provider the same questions worth asking Ro, Hims & Hers, LifeMD, or a local clinic: what the refill cadence is, what happens when a shipment slips, and who is reachable during a gap.
No equivalent rule exists for a compounded vial
Compounded tirzepatide is not FDA-approved, and no agency-reviewed label sets its concentration, its container, or its timing. The 96-hour and 72-hour figures above belong to the branded product. A missed-dose plan for a compounded preparation has to come from the prescriber who wrote it and the pharmacy that filled it.
There is a documentation problem behind this too. A study of a large primary care dataset found that compounded GLP-1 receptor agonists are frequently recorded incompletely or not at all, which means the clinician handling a gap may not know what the patient has actually been taking. Volunteering it is the only way to close that gap in the record.
Frequently asked questions
Can a smaller injection cover a week when supply is short?
There is no labeled or studied basis for it, and the label directs that product not be transferred from a pen into a syringe. Skipping the week and resuming on schedule is the documented option, and reporting the shortage is what stops the same week repeating next month.
Does one missed week undo months of progress?
No. Trial evidence on regain concerns sustained withdrawal over months, not a single skipped injection. A gap inside an established pattern is a minor event, which is why the labeling simply directs skipping it and resuming on the regular day.
What should be said if weeks were already improvised?
Say it directly, with dates and with whatever the actual amounts were. A prescriber cannot interpret the following months without it, and the alternative is a decision made on a false record. Nothing about the disclosure changes the underlying eligibility for treatment.
Does a gap in the first four weeks restart initiation?
The label does not treat the initiation period as a countdown that resets. It sets 2.5 mg once weekly for four weeks before an increase, and prescribers weigh tolerability when deciding whether the ramp has done its work. A gap during that window is worth flagging before the next step.
By
